कृपया अन्य खोज का प्रयास करें
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Ei Yamada | 72 | 2001 | CEO, President & Representative Director |
Katsunori Horikoshi | - | 2017 | Corporate Auditor |
Koichi Ando | - | 2021 | Corporate Auditor |
Naoyuki Ono | - | 2021 | Standing Corporate Auditor |
Naoya Sato | - | 2021 | Director of Corporate Development & Director |
Makoto Hara | 72 | 2018 | External Independent Director |
Norikazu Eiki | 75 | 2014 | External Independent Director |
Kimiko Murofushi | 76 | 2022 | External Independent Director |
Junichi Komamura | 73 | 2012 | External Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है